Relevance of antiphospholipid antibody profile in the clinical outcome of ITP: a single-centre study
Open Access
- 25 October 2018
- journal article
- research article
- Published by Taylor & Francis in Hematology
- Vol. 24 (1) , 134-138
Abstract
Objectives: The relevance of detecting antibodies against anticardiolipin, β2-glycoprotein I (β2gpI) or lupus anticoagulant (LA), collectively called antiphospholipid autoantibodies (APA), in subjects with immune thrombocytopenia (ITP) is still a debated issue. In particular, whether APA profile may affect the clinical course of ITP is unknown. Methods: In this study, we report our experience in a cohort of ITP patients with APA with specific interest to the relevance of different antiphospholipid antibody profiles in clinical outcome and response to treatment. Results: Thirty-seven out of 159 patients (23.2%) fulfilling ITP criteria had a platelet count ≤50 × 109/L and tested positive at APA at ITP onset. Twenty-three (62.1%) patients received at least one line of treatment for ITP. Fourteen subjects (37.8%) showing triple positivity for APA showed a significantly lower median platelet count compared to other APA patients (p = .006). Among these ITP subjects with triple positivity, 85.7% needed a treatment because of low platelet count compared to 47.8% ITP patients with non-triple-positive APA (p = .0094). ITP/APA subjects who received immunosuppressors had a higher rate of thrombosis (p = .024) as well as thrombosis developed in subjects who were on steroid therapy at a significantly higher dosage than subjects who did not develop thrombotic episodes (p < .001). When considering treatment, CR and SR rate were significantly higher in ITP/triple-positive patients compared to non-triple-positive subjects (p = .021 and p = .005). Conclusions: The profile of APA may affect the outcome of patients with ITP.Keywords
This publication has 15 references indexed in Scilit:
- The Immune Thrombocytopenia Syndrome: A Disorder of Diverse Pathogenesis and Clinical PresentationHematology/Oncology Clinics of North America, 2009
- Update of the guidelines for lupus anticoagulant detectionJournal of Thrombosis and Haemostasis, 2009
- The ITP syndrome: pathogenic and clinical diversityBlood, 2009
- The Hematologic Manifestations of the Antiphospholipid SyndromeBlood Reviews, 2008
- Antiphospholipid antibodies in adults with immune thrombocytopenic purpuraBritish Journal of Haematology, 2008
- Anti–β2‐glycoprotein I antibodies in complex with β2‐glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib‐IX‐VArthritis & Rheumatism, 2006
- Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort studyBlood, 2001
- Anti‐platelet antibodies in patients with systemic lupus erythematosus and the primary antiphospholipid antibody syndrome: their relationship with the observed thrombocytopeniaBritish Journal of Haematology, 1997
- Thrombocytopenia in the antiphospholipid syndromeBritish Journal of Haematology, 1996
- Specific antiplatelet autoantibodies in patients with antiphospholipid antibodies and thrombocytopeniaEuropean Journal of Haematology, 1994